chitosan has been researched along with Cardiomegaly in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhadra, U; Chatterjee, E; Chawla-Sarkar, M; Datta, K; Pal-Bhadra, M; Pramanik, A; Pramanik, P; Rana, S; Reddy, TL; Sarkar, S; Sen, P | 1 |
| Banerjee, D; Datta, R; Mitra, A; Naskar, S; Rana, S; Ray, A; Sarkar, S | 1 |
2 other study(ies) available for chitosan and Cardiomegaly
| Article | Year |
|---|---|
A spatio-temporal cardiomyocyte targeted vector system for efficient delivery of therapeutic payloads to regress cardiac hypertrophy abating bystander effect.
Topics: Animals; Bystander Effect; Carbazoles; Cardiomegaly; Cardiotonic Agents; Carvedilol; Cells, Cultured; Chitosan; Drug Delivery Systems; Gene Transfer Techniques; Humans; Myocytes, Cardiac; Nanoparticles; Peptides; Propanolamines; Rats, Wistar; RNA, Small Interfering; Stearic Acids; Tissue Engineering; Tumor Suppressor Protein p53 | 2015 |
Improved bioavailability of targeted Curcumin delivery efficiently regressed cardiac hypertrophy by modulating apoptotic load within cardiac microenvironment.
Topics: Acetylation; Animals; Apoptosis; bcl-2-Associated X Protein; Biological Availability; Cardiomegaly; Caspase 3; Cell Survival; Chitosan; Curcumin; Cytochromes c; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Drug Delivery Systems; E1A-Associated p300 Protein; Myocardium; Myocytes, Cardiac; Nanoparticles; Rats; Rats, Wistar; Tumor Suppressor Protein p53 | 2016 |